Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran

BACKGROUND: Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-u...

Descripción completa

Detalles Bibliográficos
Autores principales: Imani, Ali, Golestani, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2012
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829258/
https://www.ncbi.nlm.nih.gov/pubmed/24250871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829258/
https://www.ncbi.nlm.nih.gov/pubmed/24250871

Ejemplares similares